Alice T Shaw Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

12/2023	Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
5/2023	Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
1/2023	Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
12/2022	Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
1/2022	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
12/2021	Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
1/2021	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
11/2020	First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
1/2020	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
1/2020	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alice T Shaw Research Topics

Disease

84	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 10/2010
78	Neoplasms (Cancer) 11/2023 - 07/2005
54	Lung Neoplasms (Lung Cancer) 08/2023 - 07/2005
22	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2015
15	Disease Progression 01/2022 - 10/2012
14	Brain Neoplasms (Brain Tumor) 01/2023 - 02/2015
6	Diarrhea 12/2022 - 03/2014
4	Central Nervous System Diseases (CNS Diseases) 01/2018 - 12/2016
3	Cough 12/2022 - 11/2014
3	Fatigue 12/2022 - 06/2013
3	Nausea 12/2022 - 07/2018
3	Peripheral Nervous System Diseases (PNS Diseases) 12/2022 - 01/2019
3	Vomiting 12/2022 - 03/2014
3	Edema (Dropsy) 07/2022 - 01/2019
3	Adenocarcinoma of Lung 01/2018 - 06/2013
3	Melanoma (Melanoma, Malignant) 01/2017 - 05/2014
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 09/2015 - 04/2011
2	Constipation 12/2022 - 11/2014
2	Hyperlipidemias (Hyperlipidemia) 11/2020 - 01/2019
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 10/2019
2	Vision Disorders (Hemeralopia) 07/2018 - 06/2013
2	Pain (Aches) 01/2018 - 11/2014
2	Dyspnea (Shortness of Breath) 11/2014 - 06/2013
2	Neutropenia 01/2013 - 10/2012
1	Genomic Instability 08/2023
1	Sleep Initiation and Maintenance Disorders (Insomnia) 12/2022
1	Weight Gain 12/2021
1	Hypertriglyceridemia 01/2019
1	Hypercholesterolemia 01/2019
1	Colorectal Neoplasms (Colorectal Cancer) 01/2017
1	Mesothelioma 01/2017
1	Stroke (Strokes) 01/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2017
1	Mammary Analogue Secretory Carcinoma 01/2017
1	Respiratory Insufficiency (Respiratory Failure) 01/2017
1	Glioma (Gliomas) 01/2017
1	Hypertension (High Blood Pressure) 12/2016
1	Meningeal Carcinomatosis 02/2016
1	Liver Failure 01/2016

Drug/Important Bio-Agent (IBA)

69	CrizotinibIBA 05/2023 - 10/2010
58	Anaplastic Lymphoma KinaseIBA 12/2023 - 10/2010
24	Tyrosine Kinase InhibitorsIBA 12/2023 - 03/2011
22	lorlatinibIBA 12/2023 - 07/2015
22	alectinibIBA 01/2022 - 11/2014
18	Phosphotransferases (Kinase)IBA 01/2019 - 03/2011
12	ceritinibIBA 01/2020 - 01/2014
7	Circulating Tumor DNAIBA 11/2023 - 01/2017
7	ErbB Receptors (EGF Receptor)IBA 01/2020 - 03/2011
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 03/2012
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 10/2010
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2005
5	entrectinibIBA 01/2021 - 12/2015
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2015
4	Immune Checkpoint InhibitorsIBA 01/2019 - 09/2016
4	Tyrosine (L-Tyrosine)FDA Link 01/2017 - 03/2011
3	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2018
3	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 03/2015
3	brigatinibIBA 10/2018 - 05/2011
3	Docetaxel (Taxotere)FDA Link 01/2017 - 01/2013
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 12/2023 - 01/2016
2	RNA (Ribonucleic Acid)IBA 01/2023 - 12/2017
2	Alanine Transaminase (SGPT)IBA 01/2021 - 10/2012
2	cabozantinibIBA 01/2021 - 01/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 01/2016
2	osimertinibIBA 01/2019 - 04/2016
2	Pemetrexed (MTA)FDA Link 01/2017 - 11/2014
2	PlatinumIBA 01/2017 - 06/2013
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2017 - 12/2014
2	rociletinibIBA 04/2016 - 07/2015
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016 - 10/2012
2	Transaminases (Aminotransferases)IBA 03/2014 - 06/2013
1	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 12/2023
1	Cytochrome P-450 CYP2C9IBA 12/2023
1	Cytidine DeaminaseIBA 08/2023
1	Triglycerides (Triacylglycerol)IBA 12/2021
1	CholesterolIBA 12/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	capmatinibIBA 01/2021
1	Adenosine Triphosphatases (ATPase)IBA 01/2020
1	taletrectinibIBA 01/2020
1	olaparibIBA 10/2019
1	Temozolomide (Temodar)FDA LinkGeneric 10/2019
1	vasectrin IIIIBA 01/2019
1	vasectrin II (VS II)IBA 01/2019
1	SolventsIBA 10/2018
1	repotrectinibIBA 10/2018
1	NivolumabIBA 01/2018
1	Complement System Proteins (Complement)IBA 12/2017
1	Aligeron (AS 2)IBA 01/2017
1	Mitogen-Activated Protein KinasesIBA 01/2017
1	pembrolizumabIBA 01/2017
1	Lipase (Acid Lipase)FDA Link 12/2016
1	tyrosine receptor (receptor, tyrosine)IBA 01/2016

Therapy/Procedure

45	Therapeutics 08/2023 - 03/2011
9	Drug Therapy (Chemotherapy) 01/2019 - 06/2013
7	Radiotherapy 10/2018 - 02/2015
6	Immunotherapy 01/2023 - 01/2015
2	Drug Tapering 07/2022 - 02/2015
2	Aftercare (After-Treatment) 01/2020 - 02/2015
1	Molecular Targeted Therapy 01/2017